|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,430.25 GBX | -1.67% |
|
+2.94% | +6.57% |
| 02:16pm | Jet2 raised to 'buy'; Investec cuts Pagegroup | AN |
| 04:17am | Delaware Supreme Court sides with Zantac drugmakers over cancer evidence | RE |
Sales 2024 by Business Segment
Sales 2024 by Geography
Historical Breakdown of Revenue by Business Segments
Operating Income: Breakdown by Business Segment
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
Commercial Operations | - | - | 2.93TCr | 3.03TCr | 3.14TCr | |||||
D&A | - | - | 83Cr | 89Cr | 91Cr | |||||
Operating Income | - | - | 1.36TCr | 1.47TCr | 1.53TCr | |||||
Pharmaceutical Research and Development | ||||||||||
D&A | 30Cr | 32Cr | 47Cr | 57Cr | 57Cr | |||||
Operating Income | -353.8Cr | -348.9Cr | -506Cr | -560.7Cr | -584.5Cr | |||||
Dental Care Products | ||||||||||
Consumer Healthcare | 1TCr | 960.7Cr | - | - | - | |||||
D&A | 24Cr | 23Cr | - | - | - | |||||
Operating Income | 221.3Cr | 223.9Cr | - | - | - | |||||
Corporate and Other Unallocated Turnover | 2.8Cr | - | - | - | - | |||||
Operating Income | -20Cr | -37Cr | -38Cr | -26Cr | -34Cr | |||||
D&A | 8.2Cr | 5.4Cr | 11Cr | 11Cr | 7.4Cr | |||||
D&A | 78Cr | 80Cr | 74Cr | 72Cr | 100.2Cr | |||||
Corporate and Other | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
Operating Income | - | - | - | - | - | |||||
Pharmaceutical Products | ||||||||||
Pharmaceuticals - Global Pharmaceuticals | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
Operating Income | - | - | - | - | - | |||||
Vaccines | 698.2Cr | 677.8Cr | - | - | - | |||||
D&A | 40Cr | 42Cr | - | - | - | |||||
Operating Income | 271.3Cr | 225.6Cr | - | - | - | |||||
Pharmaceuticals - HIV | - | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
Operating Income | - | - | - | - | - | |||||
Pharmaceuticals | 1.71TCr | 1.77TCr | - | - | - | |||||
D&A | 56Cr | 55Cr | - | - | - | |||||
Operating Income | 772.3Cr | 817Cr | - | - | - |
Geographical Revenue Distribution History
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
United States (US) | 1.46TCr | 1.51TCr | 1.45TCr | 1.58TCr | 1.64TCr | |||||
Total Assets | 1.79TCr | 1.79TCr | 1.4TCr | 1.33TCr | 1.4TCr | |||||
Operating Income | - | - | - | - | - | |||||
International | 1.86TCr | 1.8TCr | 1.41TCr | 1.38TCr | 1.43TCr | |||||
Total Assets | 2.77TCr | 1.54TCr | 655.9Cr | 660.6Cr | 558.8Cr | |||||
Operating Income | - | - | - | - | - | |||||
United Kingdom (UK) | 98Cr | 98Cr | 70Cr | 69Cr | 71Cr | |||||
Total Assets | 627.9Cr | 661.8Cr | 513.4Cr | 646.4Cr | 780.3Cr | |||||
Operating Income | - | - | - | - | - | |||||
Total Assets | - | 506.5Cr | 541.5Cr | 533.7Cr | 537.8Cr | |||||
Total Assets | - | 655.2Cr | 3.4Cr | - | - | |||||
Inter-Segment Turnover | - | - | - | - | - |
- Stock Market
- Equities
- GSK Stock
- Financials GSK plc
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition